On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Soligenix, Inc. (SNGX) Late-Stage Biopharma with Bedrock Funding Primed for Commercial Success, Ready to Uplist to NASDAQ

For a late-stage rare diseases focused boipharma innovator like Soligenix (OTCQB: SNGX), with up to $58 million of support for its Vaccines/BioDefense segment coming directly from NIAID contract funding (National Institute of Allergy and Infectious Diseases, a division of the NIH), recent news about the success of its BioTherapeutics segment is propitiously timed, amid the company’s move to uplist to NASDAQ. The company enthusiastically executed a 1:10 reverse split early last month (http://dtn.fm/mtiM2) in preparation for the uplisting, confident that the diligent advancement of its rare diseases pipeline over the preceding years has positioned Soligenix for commercial success, with multiple Phase 2b/3 clinical programs now ready to bear fruit.

A clear 50 percent reduction in the median duration of severe oral mucositis across the board (and a noteworthy 67 percent reduction in the most severely affected) in Phase 2 clinical testing (http://dtn.fm/A7huK) on head and neck cancer patients receiving chemoradiation firmly reinforces the potential of the company’s proprietary innate defense regulator (IDR) technology, upon which Soligenix’s SGX942 (http://dtn.fm/m8wGr) (containing dusquetide) is based. Oral mucositis (breakdown and atrophy of the mouth’s mucosal lining) is one of the common problems associated with chemotherapy (as well as radiation therapy or life-threatening bacterial infections), and it represents a significant unmet medical need for which there are no currently approved therapies. Such excellent efficacy results for the Phase 2 clinical trial of SGX942 gives the company a very strong BioTherapeutics candidate to go along with its novel SGX301 (http://dtn.fm/ZavH7) topical photodynamic therapy for cutaneous T-cell lymphoma (CTCL), and SGX203 (http://dtn.fm/NCc6y) oral formulation of BDP (beclomethasone dipropionate) corticosteroid for low-toxicity treatment of Pediatric Crohn’s Disease (gastrointestinal inflammation) – both of which have received FDA Orphan Drug and Fast Track designations.

SGX942’s dusquetide formulation is a first-in-class IDR (short, fully-synthetic peptides) and this Phase 2 clinical trial data provides substantial evidence about the broad-spectrum applicability of IDR technology in other areas, like the one where it was first discovered: infectious disease. Senior VP and CMO for Soligenix, Richard Straube, MD, seemed quite proud of the SGX942 program’s success, explaining that not only does the Phase 2 data validate the same unique biology of IDRs in humans that was observed in previous animal model studies, it also serves as a positive proof of concept for expansion of the IDR platform into other indications, such as infectious disease.

Furthermore, the Phase 2 clinical trial (multi-center, double-blind, placebo-controlled) data on SGX942 reinforces a pivotal concept about IDR technology’s novel mechanism of action and how it enables an extremely promising therapeutic approach vector for a host of diseases. Because IDRs are able to directly interact with a key protein (p62, or sequestosome-1) that helps regulate natural, selective cell degradation, and thus enhance the body’s own immunological tissue-healing and anti-infective capabilities – the technology is increasingly seen by many as a sort of molecular end-run.

Able to act downstream of innate immune receptors, yet upstream from cytokine and chemokine effectors, this implementation of IDR technology is based on modulating the body’s own reaction to injury/infection, and has been shown to also delimit the inflammation associated with tissue damage. Heading off inflammation at the pass by directly interacting at the key intracellular integration point is a bold approach, and a 16 percent higher complete response (tumor completely gone) at the one-month follow up for SGX942 is nothing to sneeze at.

With a strong worldwide IP position on dusquetide and related analogs, as well as Fast Track designation from the FDA for SGX942 and solid Phase 1 safety/tolerability results under its belt, the future looks bright for Soligenix’s newest rising BioTherapeutics star. Perhaps more importantly, this further validation of the potential of the IDR technology opens the door to a broad array of targets for Soligenix, ranging from antibiotic resistant/emerging infectious diseases, to GI tract inflammation. A recent report by BCC Research puts the global market for infectious disease pharmaceuticals and vaccines at around $103.5 billion as of last year, with a roughly 7.7 percent forward CAGR through 2021, when it is anticipated that the combined value of both types will be around $212 billion.

Having secured SME status with the EMA (European Medicines Agency) (http://dtn.fm/f9uO9) as of Oct 25, earlier projections about Soligenix by analysts such as Zack’s and Aegis Capital now appear to be unmistakably materializing. EMA logistical support will go a long ways toward taking SGX942 through Phase 3, and Soligenix is now auspiciously knocking on the global pharmaceutical market’s door.

Even without really going into the company’s revolutionary thermostabilization (heat stabilization) technology ThermoVax® (http://dtn.fm/HD49d), which could eliminate cold-chain production/refrigeration and give (Alum adjuvanted) vaccines long shelf lives at even higher than normal temperatures – the attractiveness of its Vaccines/BioDefense segment should leap out at investors. By working hand-in-hand with NIAID to proactively muster force against high priority bioterrorism and emerging disease fronts, via technology platforms and specific products that are able to address the institute’s primary concerns, Soligenix has positioned itself perfectly from a developmental standpoint.

As President & CEO, Chris Schaber explained in a CEO Clips broadcast on BTV-Business Television (http://dtn.fm/eC2Pg), Soligenix has been able to brilliantly leverage its government funding in order to better manage the very cash-intensive BioTherapeutics development which has now set the company up for long-term commercial success. Soligenix’s proprietary vaccine RiVax™ (Ricin Toxin Vaccine) (http://dtn.fm/F9bYC) has been developed through a series of competitive challenge grants and the company has even demonstrated a one year stability of RiVax at prolonged elevated temperatures (104 Fahrenheit) utilizing ThermoVax technology. Properties which made Soligenix’s ThermoVax technology an ideal choice for Hawaii Biotech, Inc. when it came to dry stabilizing the key antigen for their Ebola vaccine (http://dtn.fm/5sFkv). A distinct advantage over competing Ebola vaccines, which allows the vaccine to be deployed to and easily shipped/stored within precisely those high temperature regions where Filoviruses are endemic.

Soligenix’s OrbeShield® formulation of BDP for GI-ARS (Gastrointestinal Acute Radiation Syndrome) shares considerable technical overlap with the company’s SGX203 formulation for Pediatric Crohn’s Disease, and the same deep understanding of inflammation and tissue damage is apparent in the company’s SGX201 BioTherpaeutic, designed to prevent acute radiation enteritis (inflammatory bowel syndrome resulting from radiation therapy). This kind of inflammation mastery should really inform investors about the core IP valuation of Soligenix, and even if the company’s Vaccines/BioDefense division weren’t heavily government funded, it would still be an exciting commercial biopharma play on the basis of its highly novel BioTherapeutics offerings.

It would be wise to take a closer look at the company’s first-in-class photodynamic therapy for CTCL, as well as its dusquetide IDR SGX943 (http://dtn.fm/0hAiX), designed to combat even gram-negative bacteria such as the one which causes antibiotic-resistant and potentially fatal Melioidosis infection, in order to get a better sense of just how big the end market potential is for Soligenix’s tech envelope. Soligenix’s IP position is likely the real story behind the story, and it will be very interesting to see what enhanced exposure via the NASDAQ uplifting will do.

For more information, visit www.Solgenix.com

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered